



Immune Design
Investor Relations Department
Immune Design Corp. Attn:
Accounts Payab
601 Gateway Blvd. Suite 250
South San Francisco, CA 94080
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: IMDZ

| | |
|---------------|--|
| Last Trade: | 4.25 |
| Trade Time: | 4:00 PM ET Nov 22, 2017 |
| Change: | 0.05 ↑ (+1.190%) |
| Day Range | 4.15 - 4.35 |
| 52-Week Range | 3.78 - 13.05 |
| Volume | 538,757 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Immune Design is a clinical stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVex™ and GLAAS™.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Nov 13, 2017
[Immune Design to Present at Jefferies 2017 London Healthcare Conference](#)
- Nov 7, 2017
[Immune Design Announces Multiple Presentations at CTOS and SITC Highlighting the Breadth of Existing & Future Product Candidates](#)
- Nov 1, 2017
[Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)
- Oct 27, 2017
[Immune Design to Report Third Quarter 2017 Financial Results & Provide Corporate Update](#)
- Oct 24, 2017
[Immune Design Prices \\$80.0 Million Public Offering of Common Stock](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 7, 2017
[Annual Report \(10-K\)](#)
- Apr 26, 2017
[Proxy Statement \(DEF 14A\)](#)
- Nov 1, 2017
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017
[Quarterly Report \(10-Q\)](#)
- May 4, 2017
[Quarterly Report \(10-Q\)](#)